QYQiao-Yan Yi

Qiao-Yan Yi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qiao-Yan Yi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Fan Du

    Department of Gastroenterology Fujian Medical University Union Hospital Fuzhou China

    2 shared publications
  • Lan Bai

    School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China

    2 shared publications
  • Miao He

    School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, 510006, PR China

    2 shared publications
  • Wen-Yao Zhang

    College of Longping Agricultural, College of Biology, State Key Laboratory of Chemo and Biosensing, Hunan Research Center of the Basic Discipline for Cell Signaling, and National Center of Technology Innovation for Saline-Alkali Tolerant Rice, Hunan University , Changsha 410082

    2 shared publications
  • Guangbin Jiang

    Guangxi Key Laboratory of Electrochemical and Magnetochemical Function Materials, College of Chemistry and Bioengineering, Guilin University of Technology, 12 Jiangan Road, Guilin 541004, China

    1 shared publication
  • Haiyan Shi

    Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University, Jinan 250014, China

    1 shared publication

Latest Publications

  • Progress of triazole antifungal agent posaconazole in individualized therapy

    by Yishuo Shu, Yinping Shi, Yilei Yang, Zhonghua Dong, Qiaoyan Yi, Haiyan Shi

    Posaconazole is the second-generation triazole antifungal agent with widespread clinical application. Posaconazole exposure is influenced by various factors such as drug interactions, disease state and diet, resulting in a high interindividual variability in many patients and failure to ensure therapeutic efficacy. Therefore, it is necessary to conduct individualized therapy on posaconazole to ensure the efficacy and safety of treatment. Articles were identified through PubMed using the keywords such as "posaconazole," "therapeutic drug monitoring" and "Population pharmacokinetics" from 1 January 2001 to 30 April 2022. In this paper, we review the individualized treatment studies of posaconazole from the three aspects of therapeutic drug monitoring, population pharmacokinetic study and Monte Carlo simulation to provide reference for in-depth individualized posaconazole dosing studies. This review suggests that therapeutic drug monitoring should be performed in patients taking posaconazole to adjust the dosage and assess the efficacy and cost-effectiveness of posaconazole under different clinical conditions and different dosing regimens through Monte Carlo simulations. In the future, a more detailed delineation and comprehensive examination of posaconazole PPK for specific populations requires further study.


  • Evaluation of anticancer activity in vitro and in vivo of iridium(iii) polypyridyl complexes

    by Miao He, Qiao-Yan Yi, Wen-Yao Zhang, Lan Bai, Fan Du, Yi-Ying Gu, Yun-Jun Liu, Peng Wei

    In this study, we designed and synthesized three new iridium(III) complexes [Ir(ppy)2(dmdppz)](PF6) (ppy = 2-phenylpyridine) (1), [Ir(bzq)2(dmdppz)](PF6) (bzq = benzo[h]quinolone) (2) and [Ir(piq)2(dmdppz)](PF6) (piq = 1-phenylisoquinoline, dmdppz = 5,8-dimethoxylpyrido[3,2-a:2′,3′-c]phenazine) (3). All the complexes were tested for anticancer activity by the 3-(4,5-dimethylthiazole)-2,5-diphenyltetrazolium bromide (MTT) method. These complexes showed high anticancer activity against SGC-7901 cells, and the IC50 values are 4.1 ± 0.5 for 1, 0.7 ± 0.1 for 2 and 0.6 ± 0.2 μM for 3. Additionally, complex 3 can inhibit the tumor growth in xenograft nude mice in vivo with an inhibitory percentage of tumor growth of 48.21%. Morphological studies show that the cells treated with the complexes exhibit typical apoptotic morphological characteristics such as nuclear fragmentation and chromatin condensation. Quantitative analysis by flow cytometry showed that the apoptosis rate increased sharply after the cells were exposed to the complexes, and NAC (an inhibitor that inhibits the production of ROS) can inhibit the increase of the apoptosis rate. Cell cycle studies show that complex 1 can block the SGC-7901 cell cycle at the G0/G1 phase, and complexes 2 and 3 can cause cycle arrest at the S phase. All the complexes can increase the intracellular reactive oxygen species level, and reduce the mitochondrial membrane potential, which further prompts the release of cytochrome c. In addition, the complexes can damage DNA and cause disruption of the microtubule network. In conclusion, the complexes can effectively induce cancer cell apoptosis and may be potential anticancer agents for gastric cancer.